{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:24:23Z","timestamp":1790267063360,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T00:00:00Z","timestamp":1694908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.yebeh.2023.109453","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T11:46:55Z","timestamp":1696074415000},"page":"109453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function"],"prefix":"10.1016","volume":"148","author":[{"given":"Jon Davis","family":"Perkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Abdelmoneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy Schantz","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadat","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boulenouar","family":"Mesraoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayane","family":"Melikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Alrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-Bardissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Elalamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan Jassim","family":"Al Hail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2023.109453_b0005","first-page":"S27","article-title":"Efficacy of levetiracetam in partial seizures","volume":"5","author":"Devinsky","year":"2003","journal-title":"Epileptic Disord"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109453_b0010","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","author":"Nevitt","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109453_b0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756285608094212","article-title":"Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited","volume":"1","author":"Surges","year":"2008","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109453_b0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.seizure.2014.06.004","article-title":"Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review","volume":"23","author":"Halma","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2023.109453_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review","volume":"118","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109453_b0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2165\/00002018-200730070-00001","article-title":"Negative effects of antiepileptic drugs on mood in patients with epilepsy","volume":"30","author":"Mula","year":"2007","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109453_b0035","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/00207454.2013.866951","article-title":"The adverse effects profile of levetiracetam in epilepsy: a more detailed look","volume":"124","author":"Mbizvo","year":"2014","journal-title":"Int J Neurosci"},{"issue":"11","key":"10.1016\/j.yebeh.2023.109453_b0040","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1528-1167.2009.02197.x","article-title":"Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial","volume":"50","author":"Levisohn","year":"2009","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109453_b0045","doi-asserted-by":"crossref","first-page":"e242496","DOI":"10.1136\/bcr-2021-242496","article-title":"Unusual side effects of levetiracetam","volume":"14","author":"Badarny","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109453_b0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eplepsyres.2005.10.006","article-title":"Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy","volume":"68","author":"Piazzini","year":"2006","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109453_b0055","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.yebeh.2008.05.012","article-title":"Positive and negative psychotropic effects of levetiracetam","volume":"13","author":"Helmstaedter","year":"2008","journal-title":"Epilepsy Behav"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2023.109453_b0060","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000347230","article-title":"Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients","volume":"70","author":"Koo","year":"2013","journal-title":"Eur Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109453_b0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1684\/epd.2008.0227","article-title":"Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study","volume":"10","author":"L\u00f3pez-G\u00f3ngora","year":"2008","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109453_b0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.9758\/cpn.2015.13.1.83","article-title":"The influence of levetiracetam in cognitive performance in healthy individuals: neuropsychological, behavioral and electrophysiological approach","volume":"13","author":"Magalh\u00e3es","year":"2015","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109453_b0075","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/epi.13849","article-title":"A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults","volume":"58","author":"Schoenberg","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109453_b0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yebeh.2017.10.011","article-title":"Evaluating subjective cognitive impairment in the adult epilepsy clinic: effects of depression, number of antiepileptic medications, and seizure frequency","volume":"81","author":"Feldman","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"10","key":"10.1016\/j.yebeh.2023.109453_b0085","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1212\/WNL.0000000000009061","article-title":"Antiepileptic drugs are not independently associated with cognitive dysfunction","volume":"94","author":"Foster","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109453_b0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","article-title":"Neuropsychological and behavioral effects of antiepilepsy drugs","volume":"17","author":"Loring","year":"2007","journal-title":"Neuropsychol Rev"},{"issue":"12","key":"10.1016\/j.yebeh.2023.109453_b0095","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1111\/epi.16720","article-title":"Does the accumulated antiepileptic drug load in chronic epilepsy reflect disease severity?","volume":"61","author":"Witt","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109453_b0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","article-title":"Rational polytherapy","volume":"50","author":"French","year":"2009","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2023.109453_b0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"issue":"15","key":"10.1016\/j.yebeh.2023.109453_b0110","article-title":"Effect of anti-seizure medications on functional anatomy of language: a perspective from language functional magnetic resonance imaging","volume":"24","author":"Xiao","year":"2022","journal-title":"Front Neurosci"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109453_b0115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40263-013-0063-0","article-title":"The long-term safety of antiepileptic drugs","volume":"27","author":"Gaitatzis","year":"2013","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109453_b0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109453_b0125","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.yebeh.2023.109453_b0130","series-title":"IBM SPSS Statistics for Windows, Version 26.0","author":"Corp","year":"2019"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109453_b0135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.yebeh.2008.07.012","article-title":"The effects of levetiracetam on cognition: a non-interventional surveillance study","volume":"13","author":"Helmstaedter","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109453_b0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","article-title":"The adverse event profile of levetiracetam: a meta-analysis on children and adults","volume":"31","author":"Verrotti","year":"2015","journal-title":"Seizure"},{"issue":"17","key":"10.1016\/j.yebeh.2023.109453_b0145","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/WNL.0000000000000910","article-title":"Levetiracetam reduces abnormal network activations in temporal lobe epilepsy","volume":"83","author":"Wandschneider","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109453_b0150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2006.00372.x","article-title":"Efficacy and safety of levetiracetam (up to 2000 mg\/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study","volume":"47","author":"Tsai","year":"2006","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109453_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.09.005","article-title":"Efficacy and safety of levetiracetam 1000\u20133000 mg\/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study","volume":"63","author":"Beran","year":"2005","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2023.109453_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108917","article-title":"The differential effect of levetiracetam on memory and anxiety in rats","volume":"136","author":"Zwierzy\u0144ska","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109453_b0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3988\/jcn.2008.4.3.99","article-title":"Cognitive effects of antiepileptic drugs","volume":"4","author":"Park","year":"2008","journal-title":"J Clin Neurol"},{"issue":"11","key":"10.1016\/j.yebeh.2023.109453_b0170","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.euroneuro.2015.07.027","article-title":"Adverse cognitive effects of antiepileptic pharmacotherapy: each additional drug matters","volume":"25","author":"Witt","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109453_b0175","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","article-title":"Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults","volume":"25","author":"Stephen","year":"2012","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109453_b0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14737175.2020.1707668","article-title":"The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection","volume":"20","author":"Verrotti","year":"2020","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109453_b0185","article-title":"Levetiracetam add-on for drug-resistant focal epilepsy","volume":"6","author":"Mbizvo","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.yebeh.2023.109453_b0190","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/j.1528-1167.2007.01201.x","article-title":"Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy","volume":"48","author":"Otoul","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109453_b0195","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2023.109453_b0200","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejphar.2013.10.063","article-title":"Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis","volume":"723","author":"Florek-Luszczki","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109453_b0205","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1528-1167.2008.01713.x","article-title":"Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam","volume":"50","author":"Kaminski","year":"2009","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109453_b0210","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.seizure.2012.06.013","article-title":"Self reported adverse effects of mono and polytherapy for epilepsy","volume":"21","author":"Andrew","year":"2012","journal-title":"Seizure"},{"issue":"22","key":"10.1016\/j.yebeh.2023.109453_b0215","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/01.wnl.0000281104.55418.60","article-title":"Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam","volume":"69","author":"Meador","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2023.109453_b0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2018.07.011","article-title":"Evaluation of long-term antiepileptic drug use in patients with temporal lobe epilepsy: assessment of risk factors for drug resistance and polypharmacy","volume":"61","author":"Bj\u00f8rke","year":"2018","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109453_b0225","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jamaneurol.2018.4561","article-title":"Prediction tools for psychiatric adverse effects after levetiracetam prescription","volume":"76","author":"Josephson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2023.109453_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2021.102830","article-title":"Cognitive impairment and depression: Meta-analysis of structural magnetic resonance imaging studies","volume":"32","author":"Zackov\u00e1","year":"2021","journal-title":"Neuroimage Clin"},{"issue":"6","key":"10.1016\/j.yebeh.2023.109453_b0235","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/jech-2021-218074","article-title":"Effects of depression on employment and social outcomes: a Mendelian randomisation study","volume":"76","author":"Campbell","year":"2022","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.yebeh.2023.109453_b0245","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1017\/sjp.2018.68","article-title":"Unemployment, self-esteem, and depression: differences between men and women","volume":"22","author":"\u00c1lvaro","year":"2019","journal-title":"Spanish J Psychol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023003724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505023003724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:52:31Z","timestamp":1761504751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505023003724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":48,"alternative-id":["S1525505023003724"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109453","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109453"}}